Podcasts about endeavor

Hello to you, Annie Jesperson & Nathaniel Talbot listening from Deep Harvest Farm on Whidbey Island!Coming to you from Whidbey Island, Washington this is Stories From Women Who Walk with 60 Seconds (& a bit more goodness) for Wednesdays on Whidbey and your host, Diane Wyzga.  Every week I head over to Deep Harvest Farm from July through Thanksgiving to fill my basket with organic produce as a Community Supported Agriculture (CSA) member. Early in day the CSA members get an email with a list of what's been harvested, a recipe or two and a musing by Farmer Annie like this one, The Fallacy of Sunk Costs. Maybe like me you'll recognize yourself in her words:          The Fallacy of Sunk Costs [~ by Annie Jesperson]“Sometimes a benefit and other times a detriment of long farm days are the countless hours alone with one's thoughts. A morning spent pruning tomatoes and dragging irrigation lines offers opportunity to practice deep breathing, mindfully listen to the sparrow songs or to stew on last night's sub-optimal conversation with your sister while mentally spiraling about foreign affairs.There's time for it all! We spend many moments with the gentle coo of the wind but also keep our brains stimulated with a wide assortment of podcasts. A few of us love "The Gray Area with Sean Illing," which is a philosophy show that covers culture, politics, and other big conversation topics.I'm pretty sure it was here, I learned about one of my now favorite philosophical principles that comes in handy most farm days and in the rest of life, too. It's called “The fallacy of sunk costs.” Anyone else a fan?? This concept expresses the mental error in one's tendency to keep going on an endeavor just for the sake of finishing it. You've invested some time, money, and energy so you want to complete a task even if the costs of completing it outweigh the positives. It's knowing when to cut losses and till in those overly weedy carrots, shrug your shoulders and leave the last 10% of the giant fruit tree unpruned or close the book you're not loving and pick up something else. There's nothing to gain by doing otherwise!Every day, we look at our mammoth to-do list and decide what's a priority and what just isn't going to happen and not infrequently we kiss some hard work goodbye for the sake of future plantings and more vital tasks. Prioritizing and letting go might be a farmer's most important skills as well as life talents, too, aiding us in the efficiency, time, productivity and happiness of Life!”Click HERE to visit Deep Harvest Farm,  learn about the farm & its farmers, sign up for the Seed Newsletter for hot garden tips, farm news and seed discounts, join the Community Supported Agriculture (CSA) Farm Share, AND shop the 170 varieties of Certified Organic, Open-Pollinated, & Non-GMO seed proven to thrive in the Pacific Northwest: FLOWER SEEDS  ~  VEGETABLE & HERB SEEDSThank you for listening!You're always welcome: "Come for the stories - Stay for the magic!" Speaking of magic, I hope you'll subscribe, share a 5-star rating and nice review on your social media or podcast channel of choice, bring your friends and rellies, and join us! You will have wonderful company as we continue to walk our lives together. Be sure to stop by my Quarter Moon Story Arts website, check out the Services, arrange a no-sales Discovery Call, and stay current with me as "Wyzga on Words" on Substack.ALL content and image © 2019 to Present Quarter Moon Story Arts. All rights reserved.  If you found this podcast episode helpful, please consider sharing and attributing it to Diane Wyzga of Stories From Women Who Walk podcast with a link back to the original source.Stories From Women Who Walk Production TeamPodcaster: Diane F Wyzga & Quarter Moon Story ArtsMusic: Mer's Waltz from Crossing the Waters by Steve Schuch & Night Heron Music

Seit der SPIEL 2024 erkunden Hobbyforscher mit Endeavor – Die Tiefsee die Meere. Dabei entdecken wir neue Ozeankacheln durch Sonaraktionen oder benutzen unser gewonnenes Wissen für wissenschaftliche Veröffentlichungen oder Meerestier Schutzaktionen. Wenn man das erste Mal erlebt, wie sich das Spielbrett in Endeavor Stück für Stück durch die Aktionen der Spielenden zusammenfügt, hat das auf...

Send us a textThe GSE Podcast welcomes Jennifer Zucchino (IEMA Executive Director), John Jezo (Endeavor Sales Manager), and Jenny Lescohier (Editor) to discuss the upcoming GSE Expo in Las Vegas this September and its exciting new features.• Fortbrand has acquired Xcēd, retaining all employees while expanding service offerings• IEMA has partnered with Endeavor to create an enhanced show experience with 210+ exhibitors expected• Only 25% of exhibitors are currently IEMA members despite significant benefits including 10% booth discount• The reimagined Demo Zone sponsored by PCS will feature scheduled equipment demonstrations throughout the show• The new "Layover Lounge" replaces the beer garden concept with a more inclusive social gathering space• The "Oasis" provides shaded seating with fans, phone charging, and prime viewing of demo activities• Ground Support Worldwide will present its Leaders of the Year Awards at the Expo• Registration is trending up with 2,000-2,500 attendees expected• A mobile app is being developed to enhance the attendee experience• Electric vehicles and sustainability technologies will be prominent themes throughout the showRegister at gseexpo.com to secure your spot at the GSE Expo, September 16-18 at the Las Vegas Convention Center.Looking for dependable and on demand ground support equipment leasing? Fortbrand is your go to partner. We specialize in tailored operating leases for airlines, cargo carriers, and ground handlers, delivering top tier equipment without the wait. From the latest electric GSE to traditional units, Fortbrand offers flexible terms, competitive rates, and a customer experience that is second to none. Keep your ramp moving with confidence. Visit fortbrand.com and experience GSE leasing redefined.

With Formula 1's ESPN broadcast deal set to expire, speculation is swirling around which platform the series might land on next. In this episode of StreamTime Sports, co-hosts Nick Meacham and Chris Stone debate whether Apple would be the right partner — and what the trade-offs could be. The duo also breaks down Deltatre's acquisition of Endeavor Streaming, Nick's conversation with Roger Mitchell on YouTube-first strategies, and ESPN's quiet entry into the Nordics under Disney+. Key Topics:Is Formula 1 risking its reach and sponsor value by going exclusive with Apple?What does Deltatre's acquisition of Endeavor tell us about where the value lies in the streaming tech race?Can ESPN become a major player in Europe? Or is Disney testing the water with low cost rights and brand familiarity?Are investors betting too heavily on media rights growth? Is YouTube the smarter long-term play?Why is the PGA Tour blocking Grant Horvat and other creators from filming?

Sun Tzu was a Chinese general, military strategist, writer, and philosopher who lived in the Eastern Zhou period of ancient China. Sun Tzu stresses the importance of knowing one's own strengths and weaknesses, as well as those of the enemy, to gain a strategic advantage.  Avoiding Unnecessary Conflict: A core principle is to avoid battle whenever possible, seeking to subdue the enemy through diplomacy or other means before resorting to direct confrontation.   • Psychological Warfare:  Involves manipulating the enemy's perception and actions, not engaging in personal attacks or pettiness.  I am NOT a communist sympathizer, but China got the scratch to be about that life… ***China seems to think the US wants the smoke, so China is like... bring it. I hope it is true that while they leave the MAGA trade negotiators on read, China is playing Obama speeches…I want this to be true #pettylujah From Epstein's files cover-up, to attempting to gaslight Jerome Powell, to believing the cost of a building completed 5 years ago has anything to do with current renovations, and Mr. Powell will not be bullied into crashing the world economy. Unless someone is getting handcuffed, super-sized because of swelling, due to the association with that dead pedophile, or an actual plan to reduce the deficit, I don't care about these stupid news items. They are a distraction from reality.  Crypto really is the wild, wild west. Thieves working hard to appear legit, why not work hard and just be legit? Anyone contacting you randomly on social media, trying to get you to invest your money or help them steal, is a scam. So BOLO (be on the lookout) Read more about AfroDruid Magic Elixir https://linktr.ee/tnfroisreading Racing to Buy Crypto!!! Yes, I can...Create my coin...Our rituals involve burning zeroes. Read about the financial evolution #AfroDruids $ROOTS Initial Sprouting https://tr.ee/8SIz1J4rNI   Contact us on: Blue Sky: @tvfoodwinegirl.bsky.social Threads: www.threads.net/@tnfroisreading Instagram: @tnfroisreading Facebook: TNFroIsReading Bookclub   You know your girl is on her hustle, support the show by navigating to: Dale's Angel's Store...For Merch Promo Code: tnfro Writer's Block Coffee Ship A Bag of Dicks Promo Code: tnfrogotjokes Don't forget to drop me a line at tnfroisreading@gmail.com, comments on the show, or suggestions for Far From Beale St additions.   #CryptoTrading #CryptoAirdrop #CryptoAlert @akrapheal  #AfroDruids #crypto #cryptocurrency #memecoin with a mission    

Understanding ALPA Structure, FPL, and Strategic Planning: Insights from Airline Union Leaders In this episode of Five by Five, host Captain Jason DuVernay is joined by Captain Sean Creed, Vice President–Administration/Secretary and Jade Schiewe, Executive Vice President, Group B1. As Vice President–Administration/Secretary, Sean Creed executes the policies of the Association's governing bodies and acts as custodian for all ALPA documents, contracts, leases, property deeds, and general records. He oversees ALPA's membership programs and serves as an ex officio member of the Association's Election and Ballot Certification Board. Most recently, Creed acted as ALPA's national resource coordinator and executive vice president–Group A for the Spirit Airlines pilots. Based in Chicago, Ill., he flies the Airbus A321. He's been a member of ALPA's National Strategic Planning Committee, Strategic Preparedness and Strike Committee, and the Leadership Committee. During his tenure with Spirit, he has served as both Master Executive Council (MEC) and Local Executive Council (LEC) secretary-treasurer. He was also a member of his MEC and LEC Grievance Committees. Jade Schiewe is based in Detroit, Mich., Capt. Schiewe is a Bombardier CRJ900 pilot for Endeavor and serves as Executive Vice President, Group B1, ALPA's National Resource Coordinator and a member of the Association's Strategic Planning Committee and the Structure, Services, and Finance Review Committee. In addition, Capt. Schiewe acts as his pilot group's Master Executive Council (MEC) Chair and previously served as its MEC Secretary-Treasurer and a member of its Professional Standards and Accident Investigation committees. He was also a volunteer for the Critical Incident Response Program. With elections around the corner we sit down to discuss the intricate workings of the Air Line Pilots Association (ALPA). They discuss topics such as the importance of ALPA's bottom-up structure, the role of Local Executive Councils (LECs) and Master Executive Councils (MECs), and the significance of member participation in governance. The conversation also explores the strategic planning process, the utility of Flight Pay Loss (FPL) for union volunteers, and how ALPA supports pilot groups through efforts like the Major Contingency Fund (MCF). Tune in to gain valuable insights into ALPA's operations, the role of volunteers, and the ways members can get involved and make impactful contributions.   00:30 Introduction and Guest Introductions 01:25 Overview of ALPA 301 02:19 Understanding LEC and MEC Structures 04:30 Roles and Responsibilities of MEC Officers 10:12 Importance of Pilot Participation 14:51 Effective Communication and Representation 28:49 Strategic Planning and Committee Operations 36:35 Addressing Dysfunction and Trust Issues 37:45 Importance of Honest Conversations 38:44 Role of SWOT Analysis in Strategic Planning 40:49 Communicating with Local Members 43:08 Evolution of the Strategic Planning Process 46:01 Role of The Strategic Planning & Member Resources Department in Strategic Planning 47:54 Funding and Support for Strategic Planning 56:48 Flight Pay Loss (FPL) Explained 01:04:55 Challenges and Commitment of Volunteers 01:13:17 Call for Volunteers and Closing Remarks   SUBSCRIBE   Follow us on Facebook Follow us on Instagram   Hosted by Captain Jason DuVernay

This episode recorded live at the Becker's 22nd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference features Joseph Lamplot, MD, Orthopedic Surgeon & Sports Medicine Specialist, Endeavor Health Orthopaedic & Spine Institute. Dr. Lamplot discusses consolidation in health systems, how his organization is navigating staffing pressures, the shift toward outpatient care, and the impact of AI and digital tools on efficiency and patient engagement.

Episode 530 of the Sports Media Podcast features John Pollock, a reporter and writer at POST Wrestling and the co-host of the Pollock and Thurston podcast. In this podcast we discuss the death of Hulk Hogan; Hogan's impact on the wrestling business and American sporting culture; Hogan's making the front of the April 29, 1985 issue of Sports Illustrated when the magazine was a publicity monster; why Hogan became the face and bulked-up body that led pro wrestling into America's mainstream culture; the direct line from Hogan to WWE Network's launch in February  2014 to Endeavor acquiring the WWE in a deal valuing WWE at $9.3 billion; Hogan's racism; getting booed during his Netflix appearance last January; how WWE will cover his death and more. You can subscribe to this podcast on Apple Podcasts, Spotify, and more. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

This episode recorded live at the Becker's 22nd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference features Joseph Lamplot, MD, Orthopedic Surgeon & Sports Medicine Specialist, Endeavor Health Orthopaedic & Spine Institute. Dr. Lamplot discusses consolidation in health systems, how his organization is navigating staffing pressures, the shift toward outpatient care, and the impact of AI and digital tools on efficiency and patient engagement.

This episode recorded live at the Becker's 22nd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference features Joseph Lamplot, MD, Orthopedic Surgeon & Sports Medicine Specialist, Endeavor Health Orthopaedic & Spine Institute. Dr. Lamplot discusses consolidation in health systems, how his organization is navigating staffing pressures, the shift toward outpatient care, and the impact of AI and digital tools on efficiency and patient engagement.

On this episode of the SeventySix Capital Sports Leadership Show, Wayne Kimmel interviewed the CEO of DON'T QUIT Sports Nutrition, Mark French. French has created, operated and sold multiple businesses in the consumer goods, sports, media and technology industries. As profiled by Forbes, French is recognized as one of the most successful business disruptors.Previous ventures include MISSION®, The Players' Tribune®, Healthy Together®, as well as entrepreneurial leadership roles with NBC Universal® (Founder of NBC Everywhere). French is the Founder of NLP Ventures, an investor and hands-on operational partner for portfolio companies in the Consumer Goods, Sports, Entertainment, and Technology sectors.Leading consumer PE Firm L Catterton tapped French to join them on the Board of Directors for their portfolio company X2 Performance (a clean, healthy sports energy brand) and take over the CEO role in effort to scale the business. Under French's leadership X2 partnered with Kawhi Leonard, Saquon Barkley and other elite athletes to grow the brands offering and distribution with large retailers including CVS, Subway, AMPM, GNC, etc. Mark recently led the strategic merger of X2 with Keurig Dr Pepper's sports protein brand DON'T QUIT. Under French's leadership DON'T QUIT now features clean / healthy sports beverages for all use occasions and is backed by Keurig Dr Pepper, LA Libations, Madison Square Garden, L Catterton, Sweetwater Private Equity, etc.Over the course of his entrepreneurial career, French has partnered with legendary co-founding athletes and entertainers including Dwyane Wade, Serena Williams, Derek Jeter, Carmelo Anthony, Reggie Bush, Saquon Barkley, Damar Hamlin, DJ Khaled, Kendall Toole and others. Premiere institutional investors including L Catterton, Madison Square Garden, Live Nation, Endeavor, Roc Nation, Nelson Peltz, etc have backed French and his disruptive ventures.As a philanthropist, French received the Lowell B. Mason Award for his commitment and mentorship to at-risk inner-city youth. He was one of 150 delegates selected by Pope Francis for the Global “Sport at the Service of Humanity” Council. French is an alum of Ithaca College, actively involved in the Athletic Department's Advisory Council. He graduated from Harvard's Business of Entertainment, Media, and Sports Executive Program.French's inspiring entrepreneurial story has been featured on CNBC, Forbes, ESPN, Fox Business News, and more. French is often asked to share his entrepreneurial story and teach best practices with corporate giants such as GE, The NFL and more.Mark French:LinkedIn: https://www.linkedin.com/in/mark-french-/

AfroDruids is more than a movement or some weird revolution; it is about evolution. What if you could be part of a community where everyone looks forward to the next day as another opportunity to learn something new, to create something that benefits the entire community and advances society as a whole? AfroDruids, or Crypto_Divas and Crypto_Diva_ds, are a collective of weirdos and we are about our money. We have a very low tolerance for willful obtuseness. You can't ride with us if increasing your knowledge through new experiences isn't something that interests you. Life is about change. Most experiences can change you, hopefully for the better. If you are ok with never leaving in the confines of your physical community or even to traverse past the boundaries of your county; if experiencing other people other places other foods is not appealing to you, you can't be with us. And once you become a part of the community and instead of working to make the community succesfful you opt to be a thief and breaking the law, you can't roll with us either. We look at peace as simply enjoying our lives, whether it be swimming and listening to music, whether it is creating music, whether it is creating our personalized videos, whether it's writing a book, writing a screenplay, creating our art when we can do those things undisturbed that's what we strive for. Prosperity brings of peace.  Parable of Talents, Octavia Butler's post-apocalyptic world of the United States, where the President is a felon and his minions roll around in armored trucks which are called 'maggots' using the shield of religion to justify their criminality to make 'America Great Again' while destroying it. No I am not repeating a Fox News headline, this all from a book written by a African American hermit in 1998. Reality TV...Another Season of Emily screeching on #RHOC, Lisa's lips on #RHOM blowing up like an inner tube, Ms. Nell yelling(she needs to sit down before she falls and breaks a hip) or Martel/Marsau(no difference) lying on #LoveandMarriageHuntsville. Yep, all shady opinions, but I said what I said. And Just Like That...getting into this show. No, I am not a fashion girl, although fashion is a part of my life. I am starting to lean into the storyline of the new Carrie, post Big, the lesbian Miranda, and Vertigo Charlotte. Carrie, writing a Gilded Age-like period book in her new Gramercy brownstone, ensures another season or a possible movie topic when it goes into production. Genius! Read more about AfroDruid Magic Elixir https://linktr.ee/tnfroisreading Racing to Buy Crypto!!! Yes, I can...Create my coin...Our rituals involve burning zeroes. Read about the financial revolution #AfroDruids $ROOTS Next sale in less than 2 days!! https://tr.ee/8SIz1J4rNI Blue Sky: @tvfoodwinegirl.bsky.social Threads: www.threads.net/@tnfroisreading Instagram: @tnfroisreading Facebook: TNFroIsReading Bookclub   You know your girl is on her hustle, support the show by navigating to: Dale's Angel's Store...For Merch Promo Code: tnfro Writer's Block Coffee Ship A Bag of Dicks Promo Code: tnfrogotjokes Don't forget to drop me a line at tnfroisreading@gmail.com, share your comments on the show, or suggest additions for Far From Beale St.   #CryptoTrading #CryptoAirdrop #CryptoAlert @akrapheal #AfroDruids #crypto #cryptocurrency #memecoin with a mission    

This week, we highlight the key numbers and comments from Netflix's Q2 earnings, covering finances, ad growth, live event strategy, competition, AI, and content strategy. We detail the financial metrics tied to revenue, free cash flow, debt, and estimated full-year 2025 revenue guidance. We discuss all the comments from Netflix's management team regarding measuring household engagement, its upcoming interactive ad launch, the impact of the recent price hike, its deal with TF1, and the acquisition of content assets. We also detail NBCU's decision to raise Peacock's monthly subscription by $3, as well as the new US-based SVOD service from the BBC. Finally, we discuss Deltatre's plans to acquire Endeavor Streaming, which raises questions about the state of Deltatre's business, as no metrics have been provided since its acquisition in 2022.Podcast produced by Security Halt Media

Moin und Gude,heute sitzen der Silberrücken Andreas und unser Brettspielscout Daniel zusammen und besprechen wieder so einige Spiele. Im Affenspielplatz geht es ausführlich um die "Entdeckungen"-Erweiterung zu Mischwald und einen Ausblick zu Golem, das ganze wird garniert mit einer kleinen Unmatched-Exkursion. Natürlich darf eine kleine Nachbesprechung zur Spiel des Jahrs Entscheidung nicht fehlen, wobei es hier vor allem darum geht ob Endeavor Die Tiefsee nicht doch etwas zu komplex für diesen Preis ist. Abgerundet wird das heutige Menü dann noch mit Eindrücken zu Rokkoko, Moon Colony Bloobath und Terrorscape. Viel Spaß beim Hören und Danke für euren Support,euer MonkeyTalk-TeamSupport the show

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including RAF, Sukeban, CMLL, AAA, AEW, Max, NWA, Roku, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Support #CCN by checking out mybookie.ag ! Use the code CONTROL to get a 50% bonus on your deposit! Deposit $50 & get $25, or go big and deposit $100 & get $50! Plus bet on #WWE #MITB , or any other sport on this planet! Easy deposit system & even easier withdrawals at #MyBookieGet 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

Spiel des Jahres. Najważniejsza nagroda na rynku gier planszowych za naszą zachodnią granicą. Cóż szkodzi pomarudzić? Zapraszamy do słuchania. Przy okazji czemu by nie polubić naszej stronki na Facebooku i nie zasubskrybować naszego kanału na Youtubie? Zachęcamy. MP3 do POBRANIA

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including New Mayor of NYC, LEGO, RAF, CMLL, AAA, AEW, Max, NWA, Roku, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Support #CCN by checking out mybookie.ag ! Use the code CONTROL to get a 50% bonus on your deposit! Deposit $50 & get $25, or go big and deposit $100 & get $50! Plus bet on #WWE #MITB , or any other sport on this planet! Easy deposit system & even easier withdrawals at #MyBookieGet 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

Bate papo com a corredora / triatleta Mafe Musa, que saiu de Ribeirão Preto, veio a São Paulo para estudar, fincou o pé na capital paulista se tornando diretora de aceleração de negócios na Endeavor.

Hey y'all! Join us as we discuss the My Hero Academia episode "Off to Endeavor's Agency!", including Millionaire Matchmaker memories, Japanese CIA brochures, and Endeavor's negative rizz. Want more? Visit our website, myheroanalysis.com. Thanks for listening!⁠⁠⁠⁠Fight Genocide Worldwide Master Document⁠⁠⁠⁠ ⁠⁠⁠⁠Indivisible: A Practical Guide to Democracy on the Brink⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ACLU Know Your Rights⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bother Your Representatives

Robin Clarke is the Global CEO of Passions & PR at M C Saatchi Group, where he leads the Sport & Entertainment and Talk PR divisions across North America, EMEA, and beyond. He was appointed to this role in July 2024 and sits on the agency's Executive Leadership Team under Global CEO Zaid Al‑Qassab.Bringing nearly 25 years of experience in sports and entertainment marketing, Robin began his career in sports hospitality sales before moving into advertising and agency leadership. His previous roles include Senior Business Manager at M&C Saatchi (2002–2003), Head of Fuse Sport & Entertainment at Manning Gottlieb OMD (2004–2010), and leadership positions at Starcom EMA and Publicis Media Sport & Entertainment (2010–2018).From 2018 to 2024, Robin was a key leader at 160over90 (part of Endeavor), serving first as SVP International and later as Global EVP. There, he managed major global client relationships—including DP World, Visa, AB InBev, and Marriott—and built a strong industry network.At M C Saatchi, Robin spearheads the “Cultural Power” strategy within Passions & PR, integrating sport, entertainment, and PR capabilities to deliver global campaigns and fan-focused narratives. Under his leadership, the agency has expanded client offerings across lifestyle, music, film, and large-scale sporting events, including preparations for the FIFA World Cup 2026 and Los Angeles 2028 Olympics

Welcome back to the second half of my conversation with Greg and Cathy Buffkin.In today's episode, the Buffkins speak directly to the grieving parent—especially the one who has lost a child to suicide and is wondering how to take the next breath, let alone the next step. With transparency and tenderness, they offer hard-won wisdom from their own journey, sharing what sustained them through the darkest days and how God's presence, along with the support of others, helped carry them forward.They share honestly about the emotional weight of guilt, the unique struggles of grieving as a couple, and the often-overlooked pain of surviving siblings. They also introduce us to their beautiful ministry, The Empty Chair Endeavor, and the purpose it's brought in the wake of devastating loss.This episode is filled with insight, encouragement, and a message of enduring hope for anyone navigating the deep waters of grief.Click HERE to listen to the first half of my conversation with the Buffkins.Click HERE to listen to the Empty Chair Endeavor podcast with Greg Buffkin.  Click HERE to visit the Empty Chair Endeavor website, and HERE to follow their Facebook page.  I would love to hear your thoughts on the show. Click here to send me a message! (Though I read every message, I am unable to respond through this format.) ** IMPORTANT** - All views expressed by guests on this podcast are theirs alone, and may not represent the Statement of Faith and Statement of Beliefs of the While We're Waiting ministry. We'd love for you to connect with us here at While We're Waiting! Click HERE to visit our website and learn about our free While We're Waiting Weekends for bereaved parentsClick HERE to learn more about our network of While We're Waiting support groups all across the country. Click HERE to subscribe to our YouTube channelClick HERE to follow our public Facebook pageClick HERE to follow us on Instagram Click HERE to follow us on Twitter Click HERE to make a tax-deductible donation to the While We're Waiting ministryContact Jill by email at: jill@whilewerewaiting.org

Alexis Garcia Alexis Garcia, born and raised in Miami, Florida, is an accomplished film producer, studio executive, and entrepreneur, widely recognized for his role in launching and scaling high-impact film ventures across the independent and studio landscape. He is the founder of CAT5, a turnkey production and financing company focused on high-concept, independently made action films, and co-founder of Brass Knuckle Films alongside acclaimed director Robert Rodriguez. Most recently, Garcia served as Head of Film at Fifth Season (formerly Endeavor Content), where he led the production and financing of over 40 films over 5 years. His portfolio includes major releases such as Ambulance (dir. Michael Bay), 80 for Brady (Paramount), The Peanut Butter Falcon (SXSW Audience Award), Monkey Man (dir. Dev Patel), The Long Game (SXSW Grand Jury Winner), Brawl in Cell Block 99 (starring Vince Vaughn), and The Lost Daughter (3 Academy Award nominations). In 2025, three of Garcia's movies reached audiences in a major way - A Working Man (Amazon/MGM, starring Jason Statham) opened #1 at the U.S. box office, Nonnas (Netflix) opened #1 on Netflix and became one of the platform's top titles of the year, and Friendship (SXSW premiere, starring Tim Robinson and Paul Rudd) opened as the year's top grossing limited theatrical release and was heralded as the return of the R rated cinematic comedy. Earlier, as a partner and agent at WME, Garcia helped package and sell hundreds of critically acclaimed and commercially successful films, including Drive (Nicolas Winding Refn, starring Ryan Gosling), The Nice Guys (Shane Black, starring Gosling and Russell Crowe), and The Favourite (Yorgos Lanthimos). He also spearheaded strategic initiatives such as the creation of foreign sales company Bloom, and led Endeavor's expansion into China, brokering talent ventures (Sylvester Stallone, David Goyer, Russo Brothers) and co-production deals with major studios like Perfect World, Tencent, and Village Roadshow. Garcia began his career as an entertainment attorney before joining Endeavor in 2007, rising to become a partner and later helping spin out the agency's content arm into what became Endeavor Content. He played a pivotal role in the division's growth from a sales and service operation into a vertically integrated production studio, culminating in its acquisition by CJ ENM. A graduate of Vanderbilt University with a JD from UCLA School of Law, Garcia continues to drive innovation in film production by bridging traditional Hollywood models with cutting-edge audience engagement and alternative financing strategies. He and his family (Tracy, Noa, Ozi and Busta) are proud Coconut Grove residents, having moved from Los Angeles in August of 2021.

Welcome to Which Game First where we boldly explore the hilariously huge world of board games. Did we unearth any hidden treasures you've been missing out on? Let's find out! First up: We take on the house in a cooperative game of poker in The GangNext:  We explore the depths of the ocean in search […]

This is our endeavor. To blade! To tongue! To plow! To grind our name into the bones of tomorrow, until the horizon is lucid smooth as liquid mirror, sharp as cut glass, clear as cool water rising, Irrigating in our throats the dry river bed of ambition. A witch in the gut of the tower. A wild one embraced by blood. A wizard in the court of the sword. All days divided into the days before and the days after, like the two sides of a shut window of black glass. We are:Brennan Lee MulliganErika IshiiAabria IyengarLou Wilsonand is produced, designed, and scored by Taylor Moore at Fortunate Horse with exquisite design and editing help from Jared OlsonSPECIAL THANKS TO: Shannon and Amanda Freberg! Transcript of this episode coming soon! You can find transcripts of all our episodes here, for free, on our Patreon. We're a little behind, but we're gonna catch up!Our album art is by the great Corey BrickleySome additional environmental sound design comes from Michael Ghelfi Studios. You can get their sounds and music for your home games and VTT as well, which we enthusiastically recommend. 

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including CMLL, AAA, AEW, Max, NWA, Roku, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Support #CCN by checking out mybookie.ag ! Use the code CONTROL to get a 50% bonus on your deposit! Deposit $50 & get $25, or go big and deposit $100 & get $50! Plus bet on #WWE #MITB , or any other sport on this planet! Easy deposit system & even easier withdrawals at #MyBookieGet 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

Greg and Cathy Buffkin join me on the podcast today to share the story of their son Ryan—a funny and tenderhearted young man who brought joy and laughter to everyone around him. As we get to know Ryan through their memories, we also learn about the hidden struggles he carried and the heartbreaking loss they experienced when he died by suicide in the fall of 2015.With honesty and grace, Greg and Cathy open up about the complicated grief that comes with suicide loss, including the misconceptions that often surround it. They speak directly to the false belief that suicide is the unforgivable sin, offering reassurance that Ryan knew the Lord and is with Him now. Our conversation is both tender and powerful, offering hope, truth, and the comforting reminder that God's love never lets go—even in our deepest sorrow.In this conversation, you'll hear:Stories of Ryan's life and personalityThe events leading up to his deathThe discovery of deeply painful truths after his passingHow Greg and Kathy have processed their grief over the past ten yearsThe impact of sibling loss on their surviving daughterGentle, faith-filled advice for parents grieving a suicideA reminder that God's love reaches even into our darkest placesThis episode is tender, honest, and full of hope. If you've lost a child—or know someone who has—Greg and Cathy's story will remind you that you are not alone and that God is present, even in the pain.Resources & Links:While We're Waiting – Support for bereaved parentsScripture References:Romans 8:1 – “There is therefore now no condemnation for those who are in Christ Jesus.”Romans 8:38-39 – “Nothing in all creation will be able to separate us from the love of God in Christ Jesus our Lord.”Romans 8:28 – “And we know that in all things God works for the good of those who love him…”Connect with Us:Subscribe to the podcast so you never miss an episodeLeave a review to help others find hopeVisit whilewerewaiting.org to learn more about our ministry for bereaved parentsCome back next week to hear the rest of the Buffkins' storyI would love to hear your thoughts on the show. Click here to send me a message! (Though I read every message, I am unable to respond through this format.) ** IMPORTANT** - All views expressed by guests on this podcast are theirs alone, and may not represent the Statement of Faith and Statement of Beliefs of the While We're Waiting ministry. We'd love for you to connect with us here at While We're Waiting! Click HERE to visit our website and learn about our free While We're Waiting Weekends for bereaved parentsClick HERE to learn more about our network of While We're Waiting support groups all across the country. Click HERE to subscribe to our YouTube channelClick HERE to follow our public Facebook pageClick HERE to follow us on Instagram Click HERE to follow us on Twitter Click HERE to make a tax-deductible donation to the While We're Waiting ministryContact Jill by email at: jill@whilewerewaiting.org

**REPEAT EPISODE*** So good I had to say it again… Sun Tzu was a Chinese general, military strategist, writer, and philosopher who lived in the Eastern Zhou period of ancient China. Sun Tzu stresses the importance of knowing one's own strengths and weaknesses, as well as those of the enemy, to gain a strategic advantage.  Avoiding Unnecessary Conflict: A core principle is to avoid battle whenever possible, seeking to subdue the enemy through diplomacy or other means before resorting to direct confrontation.   • Psychological Warfare:  Involves manipulating the enemy's perception and actions, not engaging in personal attacks or pettiness.  I am NOT a communist sympathizer, but China got the scratch to be about that life… ***China seems to think the US wants the smoke, so China is like... bring it. I hope it is true that while they leave the MAGA trade negotiators on read, China is playing Obama speeches…I want this to be true #pettylujah Ms. Tina Knowles Lives Woke... From Weeks Island, LA with Love Ms. Tina K. 432 pages of T—still elegant proud not stooped or bent…hearing Ms. Tina read her own words still can't replace the actual book which I will be ordering….   Reading the book or listening on Audible...you do need both in your life.... From Weeks Island to Seaside Malibu—The fire that destroyed her  home in Malibu was similar to the fire bombing that propelled her family from Weeks Island, a former plantation/salt mine, to Galveston. Still can be bound and have to be re-educated- Sewing bartered skill but only limited by your own fear, mother life of anxiety/fear rightfully so, but binding that she had to unlearn so much. Possibility to fiercely love a parent, admit that they were wrong in a lot, but still love them. The nuns in charge of the children for decades exacted vengeance and sought to humiliate and shame them out of childhood…I would have snatched that tramp's bonnet like President Biden's mama the first time she threatened or hit my kid…chile. The T-on reality TV and Pop Culture Unless you have personal video of ish being removed and returned from the Black-sonian I'm going to need you to have a seat and shut up co trolling my cortisol so should you   Weird loud white conservative making rules. And a bunch of people climbing out of their families basements and thinking you can talk crazy to people. Have seat. We all should be afraid Is it Mormon Tock or Mom tock…Sister Wives Poly Family ya'll Don't even watch TV dictating my viewing da fuck   Lock up Ky creativity and depravity   Go to your prayer closet and leave me alone #rhoa I am a Reigndrop love Monday Live recaps descent to mean girl…season 7 Porsha a mean girl dragged Kenya friend of… she literally still the same selfish airhead now. Claudia clocked it standing on business Trauma bonding 11 seasons still gutta Shame her into act right does what necessary to elevate her brand Season 7 reunion friend of Season 8 Shade Assasin Kenya deprived of us of good ol fashion Read…Regine perfect HW—Kim Fields(wanted to be regular and she was not)  not so much.  Friend of —Sharee Not even the fun Tee Tee. Porsha and single Shamea caught up in some -ish, Miami Season 9 Apex of Frick and Frack, Phaedra exits to return Season 16. If Phaedra going to be fake, not interested.  Contact Us on: https://linktr.ee/tnfroisreading Blue Sky: @tvfoodwinegirl.bsky.social Threads: www.threads.net/@tnfroisreading Instagram: @tnfroisreading Facebook: TNFroIsReading Bookclub   You know your girl is on her hustle, support the show by navigating to: Dale's Angel's Store...For Merch Promo Code: tnfro Writer's Block Coffee Ship A Bag of Dicks Promo Code: tnfrogotjokes Don't forget to drop me a line at tnfroisreading@gmail.com, comments on the show, or suggestions for Far From Beale St additions.  

In Episode 33, we review Endeavor: Deep Sea by Burnt Island Games and Grand Gamers Guild! To start off the episode, we talk about what's bringing us joy: Crokinole, Trick & Snipers, the Tokyo Game Market, and Cyclades: Legendary Edition.In Endeavor: Deep Sea, players head individual research institutes with the goal of having the most beneficial effect on the world's oceans. Over the course of six rounds, players will assemble a crew of specialists to explore the ocean, research dive sites, publish scientific Journals, and conduct conservation efforts. Many of these actions will advance their institute's attributes (Reputation, Inspiration, Coordination, and Ingenuity) and directly influence their ability to recruit team members, how much effort their team can exert, how efficiently their team functions, and the technological efficiency of their scientific vessels. All of this effort is exerted and attributes advanced in the pursuit of meeting scenario-specific Goals and creating the most positive Impact on the ocean. Be the most efficient at developing your institute and adapting to the scenario, and you'll succeed in this endeavor–just as Endeavor: Deep Sea has in the homies' hearts. Get to know us @ https://lnk.bio/BoardGameHomies

Just because something happens at the start doesn't mean it will happen forever.

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including AEW on Max Ratings, NWA deal with Roku, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Support #CCN by checking out mybookie.ag ! Use the code CONTROL to get a 50% bonus on your deposit! Deposit $50 & get $25, or go big and deposit $100 & get $50! Plus bet on #WWE #MITB , or any other sport on this planet! Easy deposit system & even easier withdrawals at #MyBookieGet 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

INTRO (00:23): Kathleen opens the show drinking a Lager For The Lakes American Lager from Bell's Brewing in Kalamazoo, MI. She reviews her weekend with family in Missouri, playing with her sister's dog and grilling for her brother-in-law on Father's Day.    TOUR NEWS: See Kathleen live on her “Day Drinking Tour.”   COURT NEWS (18:13): Kathleen shares news announcing that Dolly's new Nashville hotel will open Spring 2026, Post Malone & Jelly Roll cause a giant traffic jam in Southern Missouri, Stevie Nicks releases new Fall concert dates, and Cher's son Eligah is hospitalized again.    TASTING MENU (2:33): Kathleen samples Lesser Evil Organic Cheddar Popcorn, Lay's Wavy Magic Masala chips, Hidden Valley Jalapeno Ranch dressing, and Weber Grilling Fireball whiskey flavored seasoning.    UPDATES (23:44): Kathleen shares updates on Baby Reindeer's Fiona Harvey, the Florida Panthers win the 2025 Stanley Cup, the first Millennial saint gets his canonization date, Brooke Shields' podcast interview criticizing Meghan Markle quietly disappears, a Kentucky man is arrested for releasing a raccoon in a bar, and the 2025 NBA Finals ratings are the lowest in 27 years.   HOLY SHIT THEY FOUND IT (42:43): Kathleen reveals that Oklahoma is now producing Mountain Lions, and Captain James Cook's lost ship “The Endeavor” has been found in a Rhode Island harbor.    FRONT PAGE PUB NEWS (57:13) : Kathleen shares articles on the Louvre staff shutting the museum to protest overuse, the Bonnaroo Music Festival is cancelled due to extreme weather, Anderson Cooper's CNN contract is up for renewal, the 10,000-step exercise concept is derived from “Japanese Walking,” Red Lobster unveils a new menu, the Beach Boys' Brian Wilson dies aged 82, Country Music just got a Grammy update, Atlanta could get another NHL team, and the best fast food French fries are revealed.   STUPID TOURIST STORIES (46:25): Kathleen reads about a New Jersey tourist who is gored by a bison in Yellowstone, and a tourist crushes a priceless Van Gogh chair while taking a photo.    SAINT OF THE WEEK (1:19:22): Kathleen reads about Saint Fiacre.     WHAT ARE WE WATCHING (37:13): Kathleen recommends skipping “The Mortician” on Max, and “Titan: The OceanGate Disaster” on Netflix.   

Keith Friedenberg serves as Chief Analytics & Insights Officer of Endeavor Group Holdings, Inc. which owns and operates Ultimate Fighting Championship (UFC), World Wrestling Entertainment (WWE), William Morris Endeavor (WME), IMG, 160over90, On Location, and OpenBet/IMG Arena. Keith is founder of Endeavor Analytics, LLC, a global knowledge and insights company that provides strategic consulting, media intelligence, valuation services, and consumer insights. Endeavor Analytics boasts a global team of 80 who leverage AI & machine learning and third-party data providers to inform decision-making across media & sports properties, talent & athletes, and Fortune 500 brands. Prior to joining Endeavor in 2008, Friedenberg spent eleven years with Warner Bros. Media Research & Insights, where he supervised consumer, media and brand research operations for divisions including domestic television distribution, gaming, consumer products and emerging technology. Keith is an alumnus of the Marshall School of Business, University of Southern California.

Preparing students for tomorrow's workforce takes more than strong academics; it takes all of us working together to equip them with skills for success.From classrooms to community partners, every role matters. Today's episode explores how schools, families, and businesses can team up to build a career-ready future for every graduate.#EducationalLeader,Kim “When students are led well, they learn well.”Website: http://kimdmoore.comBook: http://leadershipchairbook.comLinkedIn: https://linkedin.com/in/kimdmooreYouTube: https://youtube.com/@EducationalLeaderThe views shared in the Educational Leadership Moment are solely mine and do not reflect the positions of my employer or any entity within the local, state, or federal government sectors.

Ben, Paul, and Trey discuss first impressions of two big games: Moon Colony Bloodbath and Endeavor Deep Sea. Somehow, we all got mad at each other in each game. Fun!We also chat about recent game plays of Dune Imperium and Wavelength, and extra bonus: the return of Games on the Brain!00:00 Intro00:57 Game Rooms08:05 Dune Imperium21:44 Wavelength33:49 Ito41:37 Landmarks of the Lost Atlas51:40 Oranges & Lemons53:00 Barcelona: The Rose of Fire54:06 Cargo Empire01:03:11 Moon Colony Bloodbath01:34:51 Endeavor Deep Sea

I'm back this week with four more shipwreck stories. We'll start with the horrific explosion of the Mississippi river steamboat, the Sultana in 1865. Next, we'll tackle the Titanic which famously sank in 1912, killing around 1,500 passengers. On to another famous ship, the Endeavor. The Endeavor was the British naval ship used by explorer Captain James Cook during his first voyage of discovery which landed him in Australia, New Zealand, and Tahiti in the mid 1700s. Later the ship changed hands and was eventually used and intentionally sunk during the American Revolutionary War. Finally, I'll end with what is, quite possibly, one of the most controversial shipwrecks ever found, the San Jose. This Spanish galleon has been called the "holy grail" of shipwrecks because it was supposedly carrying treasure worth up to 17 billion dollars today when it went down in 1708. As five plus countries argue over the San Jose's treasure, the ethical question remains - what should be done with these shipwrecks?Support the show! Join the Patreon (patreon.com/historyfixpodcast)Buy some merchBuy Me a CoffeeVenmo @Shea-LaFountaineSources: American Battlefield Trust "The Sultana Disaster"Wikipedia "Sultana"New York Times "Civil War Hull Is Reported Found"Live Science "Digital "resurrection" of the Titanic sheds light on fateful night the ship tore apart"National Geographic Press Release "National Geographic reveals groundbreaking underwater scan..."The Times "At last, the Titanic wreck is left to rust in peace"Wikipedia "James Cook"Australian National Maritime Museum "Evidence Identifying Endeavor"The Guardian "Discovery provides further evidence shipwreck is Captain Cook's Endeavor, maritime scientists say"The Guardian "Worm-eaten shipwreck of Captain Cook's Endeavor under threat from more marine animals"BBC "The fierce battle over over the 'Holy Grail' of shipwrecks"Shoot me a message!

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including R Truth, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Support #CCN by checking out mybookie.ag ! Use the code CONTROL to get a 50% bonus on your deposit! Deposit $50 & get $25, or go big and deposit $100 & get $50! Plus bet on #WWE #MITB , or any other sport on this planet! Easy deposit system & even easier withdrawals at #MyBookieGet 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

This week Shelley and I check out the SECOND of the Kennerspiel des Jahres nominees: Endeavor: Deep Sea by Carl de Visser and Jarratt Gray from Burnt Island Games and Grand Gamers Guild then have fun with a bunch of short-legged dogs in Clash of Corgis, a self-published game from Deric Drazich Thanks as always to our sponsor Bezier Games! You can support the podcast directly by becoming a sponsor www.patreon.com/garrettsgames OR you can check out our estensive list of games that no longer fit on our shelves, but belong on your table: https://docs.google.com/spreadsheets/d/16ovRDNBqur0RiAzgFAfI0tYYnjlJ68hoHyHffU7ZDWk/edit?usp=sharing

Feds blast 'Sisyphean endeavor' aim to pull back $4 billion for California High Speed Rail Please Subscribe + Rate & Review KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson wherever you listen! --- KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi & E. Curtis Johnson – KMJ’s Afternoon Drive Weekdays 2-6 PM Pacific on News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

This week on The Bludd Drop, the newest weekly segment of The Snug Wrestling Podcast, Mr. Bludd takes a deep dive into WWE's ongoing transformation in what many are calling the "Corporate Era" under TKO. Since WWE's high-profile merger with Endeavor a few years back, the company has been reshaping its identity, navigating major shifts in management, talent relations, and the overall product. Is this new era a step forward or a sign of something bigger brewing behind the scenes? Mr. Bludd shares his raw and unfiltered thoughts on the state of WWE today—don't miss it!Tune in now, and be sure to leave a star rating and review!

Feds blast 'Sisyphean endeavor' aim to pull back $4 billion for California High Speed Rail Please Subscribe + Rate & Review KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson wherever you listen! --- KMJ’s Afternoon Drive with Philip Teresi & E. Curtis Johnson is available on the KMJNOW app, Apple Podcasts, Spotify, Amazon Music or wherever else you listen. --- Philip Teresi & E. Curtis Johnson – KMJ’s Afternoon Drive Weekdays 2-6 PM Pacific on News/Talk 580 & 105.9 KMJ DriveKMJ.com | Podcast | Facebook | X | Instagram --- Everything KMJ: kmjnow.com | Streaming | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

What do bluegrass, bourbon, and Bible have in common? How about a group of Hillbilly Thomists? Today, we share an episode from the Signal Award-winning podcast, No Small Endeavor. Produced by PRX and Great Feeling Studios, No Small Endeavor explores what it means to live a good life.In this episode, you'll hear from the Hillbilly Thomists, the Billboard-charting bluegrass band made up entirely of Catholic Dominican Friars. They talk about their theology and vocation, as well as how they manage life on the road as priests who have taken a vow of poverty. Plus, they give live performances of some of their finest songs.When they are not contemplating, studying, and preaching, the Hillbilly Thomists are writing songs. They've released four albums includingHillbilly Thomists, Living for the Other Side, Holy Ghost Power, andMarigold. Marigold spent 3 weeks on the Billboard bluegrass charts, debuting at #2. The friars also have a Christmas album in the works.Proceeds from album sales, donations, and merchandise sales allow the friars to continue to produce and perform music, while providing ongoing support to the formation of friars at the Dominican House of Studies in Washington, D.C.Thanks to No Small Endeavor for sharing this episode with us.For other episodes like this one, follow No Small Endeavor on Apple Podcasts, Spotify or your favorite podcast app.Learn more about the Hillbilly ThomistsLearn more about No Small EndeavorAttend a Living Church conferenceGive to support this podcast

In our annual Spiel des Jahres special shows Ben talks to the nominees. This time it's the Kenner Spiel des Jahres  with Ben having a chat with Carl de Visser and Jarrat Gray about the game's development and their hopes for the award.Support the show hereBecome a supporter of this podcast: https://www.spreaker.com/podcast/five-games-for-doomsday--5631121/support.

For today's episode as part of the Creative Control Network, on The Business of the Business podcast with John Poz and Lavie Margolin, as we focus on The BIG NEWS of the week! We will run through a lot of the top news stories including Real American Wrestling, WWE, GCW, WWE ID, AEW, NJPW, TNA, WOW, Triller, UFC, Endeavor, CZW,GCW, WWA, NWA, ROW, and so much more!Get 20% Off and Free Shipping with the code BIZ at Manscaped.com. That's 20% off with free shipping at manscaped.com and use code BIZ. Time to feel sexy and free this 2025 with MANSCAPED™Become a supporter of this podcast: https://www.spreaker.com/podcast/the-business-of-the-business--4870725/support.

Dan Patriss is here to share the latest news from the board game world! Subscribe to the Major Spoilers Podcast Network Master Feed! Major Spoilers Podcast Network Master Feed RSS Feed Show your thanks to Major Spoilers for this episode by becoming a Major Spoilers Patron at http://patreon.com/MajorSpoilers. It will help ensure Munchkin Land continues far into the future! Join our Discord server and chat with fellow Spoilerites! (https://discord.gg/jWF9BbF) Contact us at podcast@majorspoilers.com NEWS SDJ and KDJ were announced last week 2025 Spiel des Jahres Bomb Busters Flip 7 Krakel Orakel 2025 Kennerspiel des Jahres Endeavor:Deep Sea Faraway Looot Fresh off that KDJ nomination for Endeavor:Deep Sea,  Burt Island games announced a KS will be coming soon for an expansion Endeavor Deep Sea:Uncharted Waters Arcane Wonders will release a “Duel” version of Aquatica called Aquatica Duellum, July ‘25 $45 After a recent KS success Leder Games announced they will release their 5th (?) expansion for Root called Root: The Homeland expansionin Q4 2025 (Possibly Gen Con copies and looks to be 50-60$) Atom Spotlight 2 more great people/channels I got to spend some quality time with in St. Louis in March at ATOM 25. Tabletop Bellhop -- Moe and his lovely wife Deanna have been doing this very insightful channel/podcast/reviews/demos for a long time Laura from Obsessed with Board Games is another one of those great fun follows on Instagram as she does a great job showing new board games and giving a unique insight into them. Digital BG News Dire Wolf digital has released an expansion pack for Clank! On Steam called Clank! Sunken treasures (8.99) Crowdfunding Battle Monsters: Godzilla x Kong ReWild:South America Catch 33: Dexterity/Flicking game Gamefound Trismegistus: Special Ed

Dan Patriss is here to share the latest news from the board game world! Subscribe to the Major Spoilers Podcast Network Master Feed! Major Spoilers Podcast Network Master Feed RSS Feed Show your thanks to Major Spoilers for this episode by becoming a Major Spoilers Patron at http://patreon.com/MajorSpoilers. It will help ensure Munchkin Land continues far into the future! Join our Discord server and chat with fellow Spoilerites! (https://discord.gg/jWF9BbF) Contact us at podcast@majorspoilers.com NEWS SDJ and KDJ were announced last week 2025 Spiel des Jahres Bomb Busters Flip 7 Krakel Orakel 2025 Kennerspiel des Jahres Endeavor:Deep Sea Faraway Looot Fresh off that KDJ nomination for Endeavor:Deep Sea,  Burt Island games announced a KS will be coming soon for an expansion Endeavor Deep Sea:Uncharted Waters Arcane Wonders will release a “Duel” version of Aquatica called Aquatica Duellum, July ‘25 $45 After a recent KS success Leder Games announced they will release their 5th (?) expansion for Root called Root: The Homeland expansionin Q4 2025 (Possibly Gen Con copies and looks to be 50-60$) Atom Spotlight 2 more great people/channels I got to spend some quality time with in St. Louis in March at ATOM 25. Tabletop Bellhop -- Moe and his lovely wife Deanna have been doing this very insightful channel/podcast/reviews/demos for a long time Laura from Obsessed with Board Games is another one of those great fun follows on Instagram as she does a great job showing new board games and giving a unique insight into them. Digital BG News Dire Wolf digital has released an expansion pack for Clank! On Steam called Clank! Sunken treasures (8.99) Crowdfunding Battle Monsters: Godzilla x Kong ReWild:South America Catch 33: Dexterity/Flicking game Gamefound Trismegistus: Special Ed

Bozoma Saint John has one of the most impressive résumés of all time. She's led marketing efforts at nearly every major company, including Netflix, Apple, Uber, PepsiCo, and Endeavor. In addition to her illustrious career as a marketing executive, she's also the founder and CEO of the wig company Eve by Boz, the author of the best-selling book The Urgent Life, and a recent addition to the cast of the Real Housewives of Beverly Hills. On this episode, she discusses her perspective on style—from growing up with a mother who sewed her a custom prom dress to why she decided to exclusively wear clothing from Black designers on this season of RHOBH. She also dives into how it wasn't until she began bringing her authentic self to work that she was able to step into her power and negotiate salaries like a badass.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sun Tzu was a Chinese general, military strategist, writer, and philosopher who lived in the Eastern Zhou period of ancient China. Sun Tzu stresses the importance of knowing one's own strengths and weaknesses, as well as those of the enemy, to gain a strategic advantage.  Avoiding Unnecessary Conflict: A core principle is to avoid battle whenever possible, seeking to subdue the enemy through diplomacy or other means before resorting to direct confrontation.   • Psychological Warfare:  Involves manipulating the enemy's perception and actions, not engaging in personal attacks or pettiness.  I am NOT a communist sympathizer, but China got the scratch to be about that life… ***China seems to think the US wants the smoke, so China is like... bring it. I hope it is true that while they leave the MAGA trade negotiators on read, China is playing Obama speeches…I want this to be true #pettylujah Ms. Tina Knowles Lives Woke... From Weeks Island, LA with Love Ms. Tina K. 432 pages of T—still elegant proud not stooped or bent…hearing Ms. Tina read her own words still can't replace the actual book which I will be ordering…. Reading the book or listening on Audible...you do need both in your life.... From Weeks Island to Seaside Malibu—The fire that destroyed her  home in Malibu was similar to the fire bombing that propelled her family from Weeks Island, a former plantation/salt mine, to Galveston. Still can be bound and have to be re-educated- Sewing bartered skill but only limited by your own fear, mother life of anxiety/fear rightfully so, but binding that she had to unlearn so much. Possibility to fiercely love a parent, admit that they were wrong in a lot, but still love them. The nuns in charge of the children for decades exacted vengeance and sought to humiliate and shame them out of childhood…I would have snatched that tramp's bonnet like President Biden's mama the first time she threatened or hit my kid…chile. The T-on reality TV and Pop Culture Unless you have personal video of ish being removed and returned from the Black-sonian I'm going to need you to have a seat and shut up co trolling my cortisol so should you   Weird loud white conservative making rules. And a bunch of people climbing out of their families basements and thinking you can talk crazy to people. Have seat. We all should be afraid Is it Mormon Tock or Mom tock…Sister Wives Poly Family ya'll Don't even watch TV dictating my viewing da fuck   Lock up Ky creativity and depravity   Go to your prayer closet and leave me alone #rhoa I am a Reigndrop love Monday Live recaps descent to mean girl…season 7 Porsha a mean girl dragged Kenya friend of… she literally still the same selfish airhead now. Claudia clocked it standing on business Trauma bonding 11 seasons still gutta Shame her into act right does what necessary to elevate her brand Season 7 reunion friend of Season 8 Shade Assasin Kenya deprived of us of good ol fashion Read…Regine perfect HW—Kim Fields(wanted to be regular and she was not)  not so much.  Friend of —Sharee Not even the fun Tee Tee. Porsha and single Shamea caught up in some -ish, Miami Season 9 Apex of Frick and Frack, Phaedra exits to return Season 16. If Phaedra going to be fake, not interested.  Contact Us on: https://linktr.ee/tnfroisreading Blue Sky: @tvfoodwinegirl.bsky.social Threads: www.threads.net/@tnfroisreading Instagram: @tnfroisreading Facebook: TNFroIsReading Bookclub   You know your girl is on her hustle, support the show by navigating to: Dale's Angel's Store...For Merch Promo Code: tnfro Writer's Block Coffee Ship A Bag of Dicks Promo Code: tnfrogotjokes Don't forget to drop me a line at tnfroisreading@gmail.com, comments on the show, or suggestions for Far From Beale St additions.  

Today, we are sharing an episode of “What It's Like to Be…” from author Dan Heath.  On the podcast, Dan explores the world of work, one profession at a time, and interviews people who love what they do. He finds out: What does a couples therapist think when a friend asks for relationship advice? Is a Secret Service Agent supposed to pretend like they're not there when they're around the president? What are the 3 clocks that govern the life of a long-haul truck driver? If you've ever met someone whose work you were curious about, and you had 100 nosy questions but were too polite to ask… this is the show for you. In this preview, Dan talks to Dr. Hindatu Mohammed, a veterinarian from Austin. You'll hear about how she calms scared cats with pheromone sprays. How she helps clients make hard health care decisions about their pets. You'll also learn what breed of dog, when having its nails clipped, acts like it's being murdered! You may also pick up a word that you may end up wishing you didn't know: “neuticles.”  You can listen to more episodes of What It's Like to Be at https://link.mgln.ai/nsedanheath. Want more NSE? Join NSE+ Today! Our subscriber only community with bonus episodes designed specifically to help you live a good life, ad-free listening, and early access to tickets to our live shows. Great Feeling Studios, the team behind No Small Endeavor and other award-winning podcasts, helps nonprofits and brands tell stories that inspire action. If your organization has a message that deserves to be heard, start your podcast at helpmemakeapodcast.com. Subscribe to episodes: Apple | Spotify | Amazon | Google | YouTubeFollow Us: Instagram | Twitter | Facebook | YouTubeFollow Lee: Instagram | TwitterJoin our Email List: nosmallendeavor.com See Privacy Policy: Privacy Policy Amazon Affiliate Disclosure: Tokens Media, LLC is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. Learn about your ad choices: dovetail.prx.org/ad-choices

Industrial Talk is onsite at Xcelerate 2025 and talking to Tom Wilk, Editor in Chief at Endeavor Business Media about "Emerging Industrial Technology". Scott MacKenzie and Tom Wilk discuss the Xcelerate 2025 conference in Austin, Texas, highlighting the importance of asset management, maintenance, and reliability. Tom shares his experience with Plant Services Magazine and the evolution of the conference, emphasizing the adoption of Fluke's E-Maint system by SKF, which is rolling out to 81 plants. They discuss the benefits of a CMMS for sustaining best practices and the importance of AI and mobile components in modern maintenance. Tom also notes the growing interest among younger workers in professional certifications and the need for universities to adapt to industry changes. Action Items [ ] Reach out to Tom Wilk (T Wilk) at Endeavor B2B.com or on LinkedIn to further discuss the topics covered in the meeting. Outline Introduction and Welcome to Industrial Talk Podcast Speaker 1 introduces Scott MacKenzie as a passionate industry professional dedicated to transferring cutting-edge industry innovations and trends. Scott MacKenzie welcomes listeners to the Industrial Talk Podcast, celebrating industry professionals worldwide. Scott MacKenzie thanks the audience for their support and highlights the importance of innovation, collaboration, and making the world a better place. The podcast is broadcasting from Xcelerate 2025 in Austin, Texas, hosted by Fluke Reliability. Introduction of Tom Wilkes and His Role Scott MacKenzie introduces Tom Wilkes, who has been with Plant Services Magazine for 10 years. Tom Wilkes shares his background, including his role at Plant Services Magazine and his involvement in the Accelerate conference. Tom discusses the evolution of the conference from an EMA user group to a thought leadership event focusing on plant floor operations and best practices. Scott MacKenzie and Tom discuss the importance of connected reliability and the various solutions offered by Fluke Reliability. Customer Success Stories and Implementation of E-Main Tom shares a press briefing from SKF about their successful implementation of E-Main across 81 plants worldwide. The success of E-Main led SKF's management to mandate its use across all plants due to the return on investment and streamlined work processes. Tom highlights the various ways different plants are using E-Main to optimize their maintenance programs and data management. Scott MacKenzie and Tom discuss the sustainability of these solutions and the importance of a CMMS in maintaining best practices and collective memory for the plant. Challenges and Solutions in Reliability and Maintenance Scott MacKenzie and Tom discuss the challenges of finding skilled individuals and the impact of the "silver tsunami" on organizational knowledge. Tom emphasizes the importance of investing in systems like E-Main to reduce the learning curve for new employees and maintain organizational knowledge. The mobile aspect of CMMS systems is highlighted as a key factor in getting buy-in from younger technicians. Scott MacKenzie and Tom discuss the importance of having a system like E-Main to capture and maintain organizational knowledge. Evolution of the Xcelerate Conference and Customer Focus Tom notes the subtle but significant change in the messaging at the Xcelerate conference this year, focusing more on tools already being used rather than future...